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Abstract 
Background: Epigallocatechin-3-gallate (EGCG) has anti-angiogenic, anti-oxidant, and 
anti-fibrotic properties that may have therapeutic potential in Hepatitis C Virus (HCV) 
induced cirrhosis. However, cirrhosis may impact EGCG disposition and augment its 
reported dose-dependent hepatotoxic potential.  
Objective: The safety, tolerability, and disposition of a single oral dose of EGCG in 
cirrhotic patients with HCV were examined in an exploratory fashion.   
Methods: Eleven patients with hepatitis C and detectable viremia were enrolled. Four 
had cirrhosis Child-Pugh (CP) class A, four CP class B, and three were non-cirrhotic. 
Following a single oral dose of green tea extract 400mg containing 94% pure EGCG, 
blood for EGCG was ascertained at 2, 4, and 10 hours.   
Results: Maximum plasma concentrations (Cmax) and exposures (AUC) to EGCG 
overlapped among the three groups suggesting that the disposition of EGCG is not 
significantly altered in patients with cirrhosis.   
Conclusions: A single 400 mg oral dose of EGCG was safe and well tolerated by all of 
the subjects in the study. These results provide guidance for the continued investigation 
of the long term safety and antitumor potential of EGCG in cirrhotic patients with HCV. 
 
 
 
 
 
Introduction 
Green tea, made from the unfermented leaves of Camellia sinensis, is comprised 
of several polyphenolic compounds (catechins) and can be concentrated into a green tea 
extract (GTE), which, in turn, is a common ingredient in many dietary supplements.  
Epigallocatechin-3-gallate (EGCG) is the most abundant and potent catechin contained 
within GTE, comprising typically ~40% of the total polyphenol content.
1
 EGCG has 
antioxidant, antiviral anticarcinogenic, antimutagenic, and anti-inflammatory properties, 
shown in several preclinical and epidemiologic studies
 
.
2-6  
Preclinical data in cell culture 
and animal models suggest green tea may have a role as a chemopreventative agent for 
many types of cancer, including hepatocellular carcinoma (HCC).
7-10
 
After oral absorption, tea catechins undergo extensive methylation, 
glucuronidation, and sulfation. Rapid methylation of EGCG is catalyzed by liver 
cytosolic catechol-O-methyltransferase. Methylation decreases the hydrophilicity of 
catecholic compounds; further sulfation/glucuronidation of the methylated product is 
usually needed for the elimination of the product from the body.
11,12
 There has been 
discussion that level of methylation is influenced by polymorphisms of catechol-O-
methyltransferase,  but the effect of this has not yet been fully studied. Within the plasma,  
serum albumin contributes to transport and stabilization by directly preventing EGCG 
oxidation. Therefore, low serum albumin may decrease EGCG plasma levels.
13
 
The safety and pharmacokinetics of EGCG in patients with cirrhosis has not been 
described.  This may reflect concerns regarding a risk for hepatotoxicity with EGCG, 
especially where such risk may be unpredictable due to differences in EGCG’s 
disposition in this patient population as a result of the underlying liver disease.  Reports 
of hepatitis associated with the consumption of green tea preparations have been 
published.
14-16
 The mechanism of the potential hepatotoxicity of GTE is unclear.
13 
However it can be hypothesized that the impact of a hepatotoxic event may be magnified 
in patients with preexisting liver disease as a result of alterations in pathways involved in 
EGCG’s hepatic metabolism or excretion.  Differences in the disposition of silymarin, 
another herbal product used by patients for the self-treatment of liver disease, has been 
seen in liver disease.
17,18
 Alterations in the expression of hepatobiliary transporters 
induced by liver disease, which may lead to differences in drug disposition, have been 
reported.
19
 
The risk of hepatic decompensation as a result of drug induced liver injury is 
greatest in patients with cirrhosis and increases with disease progression defined by Child 
Pugh classification
.20 
 The main goal of this study was to estimate EGCG exposure 
following a single oral dose of a green tea extract highly concentrated base EGCG, using 
a limited pharmacokinetic sampling schedule, in Child Pugh class A and B patients, and 
in non-cirrhotic patients with HCV.  Furthermore, this study establishes the safety and 
tolerability of EGCG at the dose selected and serves as rationale for larger scale dose 
escalation and multiple dose studies in this potentially vulnerable population. 
 
Patients and Methods 
Study Participants 
Adult patients with HCV viremia, and cirrhosis status assessed by prior biopsy or 
imaging were recruited from Thomas Jefferson University Hepatology practice for 
inclusion in the study.  Exclusion criteria were prior liver transplantation, hepatocellular 
cancer, and current HCV treatment.   
Study Protocol  
 This was an open label, single dose, clinical trial. The study protocol was 
approved by the Thomas Jefferson University Institutional Review Board and all study 
subjects provided written informed consent. Subjects were asked to refrain from ingestion 
of tea or tea containing products for 14 days prior to the day of the study. The day before 
the study participants were instructed to fast after midnight except for drinking water.  
Subjects were given a single oral dose of 400mg 94% pure EGCG (TEAVIGO
®
 DSM 
Nutritional Products Ltd).  Additional compounds within the product include non-EGCG 
catechins (epicatechingallate, epicatechin, catechin, gallocatechin gallate, and gallic acid) 
at less than 5.3%.  
Patients were housed in the Clinical Research Unit (CRU) for the 10 hour duration of the 
study after administration of EGCG. Blood EGCG levels and safety parameters 
(including complete blood count, comprehensive metabolic panel, and coagulation panel) 
were ascertained at baseline and at 2, 4, and 10 hours post dosing.  Phlebotomy was 
performed by venipuncture.  Plasma samples were collected in BD Vacutainer® venous 
blood collection tubes and CryoVial® collection tubes.  Using P10 pipette, 10 microliters 
(10 ul) of Formic Acid and P100 pipette, 30 microliters (30 ul) of Ascorbic acid solution 
was added for every 1 milliliter of plasma,  Tubes were then inverted for 5 seconds to 
mix thoroughly to ensure proper stability of EGCG in plasma,  Samples were then stored 
in a -80º freezer until analysis. 
 
Subjects were fed 4 hours after dosing. The fasting condition and sampling times 
were based on previously published limited sampling strategy models which had greater 
predictive performance under fasting conditions and were shown to accurately predict 
EGCG oral clearance in healthy subjects.
21 
 Follow up safety labs were drawn 8 to 15 
days after dosing.  
Analysis of EGCG Plasma Concentrations 
Plasma samples for EGCG were analyzed using LC–MS with negative ion 
electrospray ionization.  The assay has a detection limit of 2ng/ml and is linear in the 
range of 2-5000ng/ml. The accuracy for EGCG quantification was 79.8% and intra- and 
interday precisions were 1.7 to 7.9% and 3.7 to 9.6%, respectively. 
Pharmacokinetic Analysis 
 Estimated area under the curve for the limited sampling strategy (AUCLSS 
0→10) was calculated with the trapezoidal rule.  Half-life (t1/2) was calculated from the 
measurements obtained at 4 and 10 hours post-dosing.  Geometric means for AUC and 
t1/2 were computed for cirrhotics and non-cirrhotic controls, along with 95% confidence 
intervals, but the small sample sizes precluded a direct statistical comparison.  The 
analyses were conducted in SAS 9.3. 
Results: 
 Eleven subjects were enrolled; four with Child-Pugh Class A, four with Child-
Pugh class B, and three non-cirrhotic subjects (Table 1). The median EGCG 
concentrations and pharmacokinetic estimates are summarized in Table 2 and Figure 1... 
The Cmax was 89 ng/ml in non-cirrhotics at 2 hours; 182 ng/ml at 2 hours in cirrhotics.  
The AUC increased with more advanced liver disease; that is, the exposure to EGCG was 
higher in cirrhotic patients than in the noncirrhotic patients.  Three patients had detectable 
EGCG noted on baseline EGCG concentration labs. Upon later questioning, the subjects 
reported tea intake (not labeled as green tea) despite being asked to refrain from tea for 
14 days prior to the study day. One class B cirrhotic had highly increased EGCG 
concentrations at baseline that were unable to be verified; therefore, these the data from 
this subject were excluded from final analysis. Figure 1 shows EGCG concentration over 
dosing day. Of note, Child Pugh subject A3 appeared to have an exposure greater than 
any other subject.  No drug related adverse events were reported during the study or at 
the follow up safety visit. Two of the four Child-Pugh Class B subjects had a rise in their 
total bilirubin (over 2 mg/dL) noted on follow up safety labs drawn 8 to 15 days after 
dosing day, although these elevations were within the patients’ observed retrospective 
range. 
 
Discussion: 
In this study we provide the first description of EGCG pharmacokinetics in patients 
with chronic HCV infection.  The rationale for the study is predicated upon EGCG’s 
potential therapeutic benefit in this patient population; specifically, its antiviral and 
antitumor effects.  However, given the hepatotoxic potential of green tea extract and the 
potential for augmented hepatotoxicity in patients with chronic liver disease, it is important 
to have established safety and tolerability, even if only at one dose, before proceeding to 
additional studies.  While point estimates of EGCG AUC suggest systemic exposure that is 
higher in cirrhotics than in non-cirrhotics, the relatively small number of patients, PK 
collection samples, and intersubject variability suggest that the study is underpowered to 
detect a true difference, should one exist.  This study presents exploratory data only; future 
studies will need to incorporate more subjects. However, the data do provide a broad 
estimate of EGCG disposition in this population, and show overlap between the three study 
panels. 
Approximately 2% of the US population is infected with HCV; cirrhosis develops 
in 20% of those infected and HCC develops in 25% of cirrhotics, most of whom die from 
their disease.
8,22 
 EGCG has been found to be a potent inhibitor of HCV entry in hepatoma 
cell lines as well as primary human hepatocytes.
23,24
  Beyond its antiviral effect on HCV, 
and germane to its potential use as a chemopreventative or chemotherapeutic agent for 
hepatocellular cancer, recent data indicate that the receptor tyrosine kinases are one of the 
critical targets of EGCG to inhibit cancer cell growth. EGCG has also been shown to 
modulate the expression of target genes which are associated with induction of apoptosis 
and cell cycle arrest in cancer cells.
25  EGCG’s chemopreventative effect has been 
demonstrated in human subjects with chronic hepatitis B and a very high risk of 
hepatocellular carcinoma.
10 
GTE is a common ingredient in several dietary supplements, some of which have 
been withdrawn from the market due to safety concerns. An example of this is Exolise 
(Arkopharma,France), a weight loss supplement containing high EGCG levels was 
withdrawn from the market in April 2003 due to 13 cases of attributable liver injury.
26   
Since 1966, 216 case reports of toxicity with green tea extracts were identified by the 
United States Pharmacopeia, of which 34 were concerning for liver toxicity.
13 
 The 
majority of cases present with an acute hepatocellular injury pattern and most recover 
with cessation of use.
12,26,27
  Based on this review, no significant safety issues were 
identified that would prohibit further development of green tea extract containing dietary 
supplements.  An idiosyncratic or an immune-allergic mechanism appears to be the likely 
mechanism of injury.
   
Recent animal studies with high doses of GTE and EGCG have 
described dose dependent hepatotoxicity resulting in severe morbidity and mortality.
28 
However, chronic moderate to high dose daily GTE and EGCG use in healthy human 
volunteers was not shown to cause severe adverse effects or impair liver function.
29-32 
Prior pharmacokinetic studies have established peak blood concentrations and 
exposures of EGCG associated with its safety and tolerability in healthy subjects.
30-34 
 In 
a study by Chow et al., following a single 800mg dose of EGCG in five healthy 
volunteers, AUC (min·µg/ml) ±SD was 167.1 ± 57.0, Cmax (ng/mL) was 438.5 ± 28.4 and 
t1/2 (min) was 114.0 ± 33.3.
35 
 In a multi-dose study by Chow et al., volunteers were 
randomly assigned to receive one of the five treatments for 4 weeks: 800 mg EGCG 
once/day, 400 mg EGCG twice/day, 800 mg EGCG as Polyphenon E once/day, 400 mg 
EGCG as Polyphenon E twice/day, or a placebo once/day (8 subjects/group).  There was 
a >60% increase in the area under the plasma EGCG concentration-time curve after 4 
weeks of green tea polyphenol treatment at a dosing schedule of 800 mg once daily. No 
significant changes were observed in the pharmacokinetics of EGCG after repeated green 
tea polyphenol treatment at a regimen of 400 mg twice daily. The described dose range, 
which was equivalent to 8–16 cups of green tea/day, and frequency of administration of 
EGCG in these study appeared to be well tolerated.
30 
The EGCG dosing in these 
pharmacokinetic studies is similar to the chronic dosing studies noted above which also 
showed no hepatotoxicity.
30,31 
A limited pharmacokinetic sampling schedule was employed in the current study 
to obtain reasonable estimates of EGCG exposure while not exposing ill subjects to 
excessive phlebotomy.  Chow et al. employed modeling and Monte Carlo simulation to 
formulate a limited sampling that accurately predicted pharmacokinetic parameters 
following EGCG administration up to 800 mg in healthy volunteers.
30 
 Limited sampling 
strategies have been shown to  provide estimates of EGCG exposure, within a specific 
dosing range, that are similar to the more dense sampling pharmacokinetic 
investigations.
21 
The half life estimates were unchanged across patient populations, and were similar 
to those noted by Chow in healthy subjects.  In comparison, the point estimates of AUC0-10 
were larger in cirrhotics compared to non-cirrhotics (1281 vs. 670 min•ng/ml), though there 
was significant overlap and these differences were not statistically significantly different.  
A limitation of this study is the fact that baseline EGCG levels were detectable in a few 
patients at low levels despite being asked to refrain from green tea products. These low 
values that did not materially impact the pharmacokinetic parameter estimation. While 
there was intersubject variability noted in the AUC0-10 value, there does appear to be 
suggestion of a disease severity related effect on systemic exposure at similar doses of 
orally administered GTE.  The mechanism by which this could occur could be increased 
extent of absorption or enterohepatic recirculation.  Alternatively, decreased total clearance 
would need to be paired with an increase in volume of distribution to maintain an 
unchanged t1/2.  The current study does not provide guidance about the mechanism by 
which the currently observed differences could be explained. 
 
Conclusions: 
Overall, a single 400 mg oral dose of EGCG was safe and well tolerated. However, 
due to our small sample size and variability in pharmacokinetic exposures, detection of 
exposure differences or hepatotoxicity risk between were not identified.  In addition, the 
single dose design of our study does not allow for evaluation of dose- and time-dependent 
hepatotoxicity risk.  Overall, the exposures observed in our study suggest that the 
disposition of EGCG is not significantly altered in patients with cirrhosis; chronic dosing 
studies should be conducted to define the safety risk in this patient population.  
Given its potential role as an adjunct to HCV triple therapy and as a 
chemopreventative agent in the HCV cirrhotic population, our findings support the conduct 
of a Phase I chronic dose-escalation study and multiple dose study eventually leading to a 
large-scale efficacy and chemoprevention trials.  In light of the hepatotoxic potential of 
EGCG, future studies should be limited to patients with early stage (Childs Pugh Class A) 
cirrhosis, who remain at risk for HCC, who are monitored carefully for early signals of 
hepatotoxicity. 
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Figure 1: EGCG concentrations over time (dosing day). 
 
EGCG concentration over time in cirrhotics and non-cirrhotic controls (open circles and 
squares, respectively), along with geometric means and 95% confidence intervals for 
each group (closed circles and squares). 
 
 
